Production (Stage)
D
Celldex Therapeutics, Inc. CLDX
$20.49 -$0.77-3.62% NASDAQ
Recommendation
Prev Close
$21.26
Volume
579,743
Avg Vol (90D)
875,361
Market Cap
$1.41B
Dividend & Yield
--
52-Week Range
$14.40 - $47.00
P/E (TTM)
--
EPS (TTM)
-$2.70
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Q2 Earnings Estimate for CLDX Issued By Lifesci Capital
6/16/2025 - MarketBeat
Celldex Therapeutics Inc (CLDX) Reports Promising Phase 2 Results for Barzolvolimab in Treating ...
6/14/2025 - GuruFocus
Celldex Therapeutics Inc (CLDX) Reports Promising Phase 2 Results for Barzolvolimab in Treating ...
6/14/2025 - GuruFocus
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
6/14/2025 - Globe Newswire
Celldex Therapeutics (NASDAQ:CLDX) Trading Up 9% - Here's Why
6/13/2025 - MarketBeat
Celldex Therapeutics (CLDX) Maintains "Buy" Rating with $50 Target CLDX Stock News
6/13/2025 - GuruFocus
Celldex Therapeutics Inc (CLDX) Reports Promising Phase 2 Results for Barzolvolimab in Chronic ...
6/12/2025 - GuruFocus
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
6/12/2025 - Globe Newswire
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
6/11/2025 - Zacks Investment Research
One Celldex Therapeutics Insider Raised Stake By 40% In Previous Year
6/11/2025 - Simply Wall St
Celldex Therapeutics Inc (CLDX) Announces Presentation of Phase 2 Study Data at EAACI Congress ...
6/10/2025 - GuruFocus
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
6/10/2025 - Globe Newswire
Equities Analysts Issue Forecasts for CLDX FY2026 Earnings
6/10/2025 - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 4.5% - Should You Sell?
6/9/2025 - MarketBeat
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Bank of America Corp DE
6/7/2025 - MarketBeat
Celldex Therapeutics (CLDX, $21.35) price may drop as it broke higher Bollinger Band on Jun 06, 2025
6/7/2025 - Tickeron - Stocks
Celldex Therapeutics (CLDX, $21.35) Moving Average Convergence Divergence (MACD) Histogram turned positive on June 6, 2025
6/7/2025 - Tickeron - Stocks
Celldex Therapeutics Inc (CLDX) Welcomes Denice M. Torres to Board of Directors CLDX stock news
6/6/2025 - GuruFocus
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
6/6/2025 - GuruFocus
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors CLDX Stock News
6/6/2025 - GuruFocus
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
6/6/2025 - Globe Newswire
17,000 Shares in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Purchased by Apella Capital LLC
6/6/2025 - Ticker Report
Apella Capital LLC Invests $309,000 in Celldex Therapeutics, Inc. (NASDAQ:CLDX)
6/6/2025 - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)
6/6/2025 - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume - Here's Why
6/4/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$7.56M
EBITDA (TTM)
-$213.94M
EBIT (TTM)
-$217.21M
Net Income (TTM)
-$178.85M
Balance Sheet
Total Assets (Q)
$739.47M
Total Debt (Q)
$3.43M
Total Liabilities (Q)
$36.49M
Book Value Per Share (Q)
$10.59
Cash Flow
Cash from Operations (TTM)
-$171.51M
Cash from Investing (TTM)
$68.03M
Cash from Financing (TTM)
$5.54M
Net Change in Cash (TTM)
-$97.94M
Filings
Filing Date
Thursday, May 8, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
1.62
7-Day Total Return
4.92%
30-Day Total Return
-0.82%
60-Day Total Return
3.07%
90-Day Total Return
-14.59%
Year to Date Total Return
-20.55%
1-Year Total Return
-40.90%
2-Year Total Return
-45.51%
3-Year Total Return
-4.83%
5-Year Total Return
91.32%
52-week Low
Apr 09, 2025 - $14.40
52-week High
Sep 25, 2024 - $47.00
Valuation
Market Cap
$1.41B - Small Cap
Enterprise Value
$741.68M
Price/Sales (TTM)
186.82
Price/Book (Q)
2.01
Dividends and Shares
Shares Outstanding
66.38M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.celldex.com
Phone Number
908 200 7500
Address
Perryville III Building
Suite 220 - 53 Frontage Road
Hampton, NJ 08827
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The... more
NASDAQ 06/16/2025 1:21PM Eastern Quotes delayed